SILK Laser Australia Limited

ASX:SLA Stock Report

Market Cap: AU$177.4m

SILK Laser Australia Valuation

Is SLA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SLA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SLA (A$3.34) is trading above our estimate of fair value (A$1.02)

Significantly Below Fair Value: SLA is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SLA?

Key metric: As SLA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SLA. This is calculated by dividing SLA's market cap by their current earnings.
What is SLA's PE Ratio?
PE Ratio24.5x
EarningsAU$7.24m
Market CapAU$177.42m

Price to Earnings Ratio vs Peers

How does SLA's PE Ratio compare to its peers?

The above table shows the PE ratio for SLA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average23.6x
HLA Healthia
46.1xn/aAU$252.1m
AHX Apiam Animal Health
14.6xn/aAU$72.1m
ACL Australian Clinical Labs
29.2x16.0%AU$697.9m
FCG Freedom Care Group Holdings
4.5xn/aAU$4.0m
SLA SILK Laser Australia
24.5x28.9%AU$177.4m

Price-To-Earnings vs Peers: SLA is good value based on its Price-To-Earnings Ratio (24.5x) compared to the peer average (24.7x).

Price to Earnings Ratio vs Industry

How does SLA's PE Ratio compare vs other companies in the Global Healthcare Industry?

11 CompaniesPrice / EarningsEstimated GrowthMarket Cap
SLA 24.5xIndustry Avg. 20.6xNo. of Companies76PE01632486480+
11 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SLA is expensive based on its Price-To-Earnings Ratio (24.5x) compared to the Global Healthcare industry average (22.5x).

Price to Earnings Ratio vs Fair Ratio

What is SLA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SLA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio24.5x
Fair PE Ratio29.3x

Price-To-Earnings vs Fair Ratio: SLA is good value based on its Price-To-Earnings Ratio (24.5x) compared to the estimated Fair Price-To-Earnings Ratio (29.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

SDI

AU$122.4m

Engages in the research and development, manufacture, and marketing of dental restorative materials, whitening systems, and other dental materials in Australia, Europe, the United States, and Brazil.

SDI

AU$1.03

7D

-4.2%

1Y

30.4%

CardieX

AU$30.9m

Engages in the design, manufacture, and marketing of medical devices used in cardiovascular health management in the Americas, Europe, and the Asia Pacific.

CDX

AU$0.10

7D

-22.2%

1Y

n/a

Nova Eye Medical

AU$34.4m

Designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally.

EYE

AU$0.15

7D

-1.6%

1Y

13.0%